Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 9/2015

01-09-2015 | Prostate Cancer (A Kibel, Section Editor)

Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers

Authors: Todd Morgan, Ganesh Palapattu, John Wei

Published in: Current Urology Reports | Issue 9/2015

Login to get access

Abstract

Urology has been beset by several major trends that have shifted the entire paradigm for prostate cancer screening. These stem from a backlash against overdiagnosis and overtreatment due to prostate-specific antigen (PSA)-based screening efforts and have led national societies to modify their guidelines. More importantly, the public outcry has shifted the focus of early detection from an effort to diagnose any and all prostate cancers to an effort to diagnose clinically significant prostate cancers at an early stage. This review provides an update on contemporary biomarkers for prostate cancer that may be used to supplement PSA-based screening approaches.
Literature
1.
Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.PubMedCentralPubMedCrossRef
2.••
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35. The risk of dying from prostate cancer decreased significantly after just 11 years of follow-up in this pivotal PSA screening trial. After 13 years of follow-up, one prostate cancer death was prevented for every 781 men screened for prostate cancer with PSA.PubMedCrossRef
3.
Chou R, LeFevre ML. Prostate cancer screening—the evidence, the recommendations, and the clinical implications. JAMA J Am Med Assoc. 2011;306(24):2721–2.CrossRef
4.
5.
Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol. 1997;15(6):331–5.PubMedCrossRef
6.
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78.PubMedCrossRef
7.
Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650–5.PubMedCentralPubMedCrossRef
8.
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.PubMedCrossRef
9.
Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61(18):6958–63.PubMed
10.••
Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol. 2013;63(6):986–94. In this large multicenter prospective cohort study [-2]proPSA and the prostate health index demonstrated improved prediction over using just total PSA and free PSA. Using decision curve analyses, it was estimated that use of these new tests yielded an optimal benefit when the likelihood of having a positive biopsy was between 30 and 60%.PubMedCrossRef
11.
Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1193–200.PubMedCentralPubMedCrossRef
12.
Naya Y, Okihara K. Role of complexed PSA in the early detection of prostate cancer. J Natl Compr Canc Netw. 2004;2(3):209–12.PubMed
13.
Rhodes T, Jacobson DJ, McGree ME, et al. Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology. 2012;79(3):655–61.PubMedCentralPubMedCrossRef
14.
Rhodes T, Jacobson DJ, McGree ME, et al. Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men. J Urol. 2012;187(1):87–91.PubMedCentralPubMedCrossRef
15.
Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2013;112(6):717–28.PubMedCrossRef
16.
Peltola MT, Niemela P, Vaisanen V, et al. Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades. Urology. 2011;77(4):1009. e1001-1008.PubMedCrossRef
17.
Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. 2011;20(2):255–61.PubMedCentralPubMedCrossRef
18.
Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer. Rotterdam Clin Cancer Res. 2010;16(12):3232–9.PubMedCrossRef
19.
Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975–9.PubMed
20.
Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. [see comment]. Eur Urol. 2003;44(1):8–15. discussion 15–16.PubMedCrossRef
21.
Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–10.PubMedCrossRef
22.
Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311–5. discussion 315–316.PubMedCrossRef
23.
Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52(6):1089–95.PubMedCrossRef
24.
Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 2004;46(2):182–6. discussion 187.PubMedCrossRef
25.
van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13(3):939–43.PubMedCrossRef
26.
Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532–5.PubMedCrossRef
27.
Tombal B, Ameye F, de la Taille A, et al. Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. World J Urol. 2011.
28.
Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–8.PubMedCrossRef
29.
Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol. 2012.
30.
Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl. 2014;16(3):487–92.PubMedCentralPubMedCrossRef
31.••
Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32(36):4066–72. In this NCI funded clinical study, PCA3, using discrete cutoffs, was validated in the setting of an initial prostate biopsy as well as a repeat prostate biopsy to aid in the diagnosis of prostate cancer. When PCA3 is added to clinical risk factors, as captured by the PCPT nomogram, it significantly improved the detection of any prostate cancer as well as high grade prostate cancer.PubMedCrossRef
32.
Hansen J, Auprich M, Ahyai SA, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013;63(2):201–9.PubMedCrossRef
33.
Ruffion A, Devonec M, Champetier D, et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci. 2013;14(9):17767–80.PubMedCentralPubMedCrossRef
34.
Vedder MM, de Bekker-Grob EW, Lilja HG, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol. 2014.
35.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(644).
36.
Tomlins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer. Eur Urol. 2014;65(3):543–5.PubMedCrossRef
37.
Young A, Palanisamy N, Siddiqui J, et al. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol. 2012;138(5):685–96.PubMedCentralPubMedCrossRef
38.
Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.PubMedCentralPubMed
39.
Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–42.PubMedCrossRef
40.
Chan SW, Nguyen PN, Violette P, et al. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Med. 2013;2(1):63–75.PubMedCentralPubMedCrossRef
41.
Tallon L, Luangphakdy D, Ruffion A, et al. Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. Int J Mol Sci. 2014;15(8):13299–316.PubMedCentralPubMedCrossRef
42.
Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392–8.PubMedCrossRef
43.
Mehra R, Shi Y, Udager AM, et al. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia. 2014;16(12):1121–7.PubMedCentralPubMedCrossRef
44.•
Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014;15(13):1469–80. Long non-coding RNA have increasingly been identified as having functions other than transcription and typifies how biology and biomarker discovery converges. SChLAP1, a long non-coding RNA, was identified as the highest-ranked overexpressed gene in cancers with metastatic progression, giving it potential to be a highly prognostic biomarker.PubMedCrossRef
Metadata
Title
Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers
Authors
Todd Morgan
Ganesh Palapattu
John Wei
Publication date
01-09-2015
Publisher
Springer US
Published in
Current Urology Reports / Issue 9/2015
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0537-3

Other articles of this Issue 9/2015

Current Urology Reports 9/2015 Go to the issue

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Nocturia: Current Evaluation and Treatment for Urology

Office Urology (N Shore, Section Editor)

Use of Advanced Practice Providers as Part of the Urologic Healthcare Team

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Tolterodine in the Treatment of Male LUTS

Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

Management Strategies for Post-Prostatectomy Bladder Neck Contractures

Genetics and Microenvironment (X Cathelineau, Section Editor)

Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Controversies in the Management of Vesicoureteral Reflux